Published in Virol J on December 29, 2012
Towards the knowledge-based design of universal influenza epitope ensemble vaccines. Bioinformatics (2016) 0.83
Protective Efficacy of the Conserved NP, PB1, and M1 Proteins as Immunogens in DNA- and Vaccinia Virus-Based Universal Influenza A Virus Vaccines in Mice. Clin Vaccine Immunol (2015) 0.80
Intranasal delivery of influenza rNP adjuvanted with c-di-AMP induces strong humoral and cellular immune responses and provides protection against virus challenge. PLoS One (2014) 0.79
Expression of H3N2 nucleoprotein in maize seeds and immunogenicity in mice. Plant Cell Rep (2015) 0.79
Broadly protective immunity against divergent influenza viruses by oral co-administration of Lactococcus lactis expressing nucleoprotein adjuvanted with cholera toxin B subunit in mice. Microb Cell Fact (2015) 0.77
Cross-protective immunity against influenza A/H1N1 virus challenge in mice immunized with recombinant vaccine expressing HA gene of influenza A/H5N1 virus. Virol J (2013) 0.77
Heterologous protection against influenza by injection of DNA encoding a viral protein. Science (1993) 10.14
Cytotoxic T-cell immunity to influenza. N Engl J Med (1983) 8.49
Influenza. Lancet (1999) 4.77
Influenza vaccine: the challenge of antigenic drift. Vaccine (2007) 4.23
The influenza virus nucleoprotein: a multifunctional RNA-binding protein pivotal to virus replication. J Gen Virol (2002) 3.77
Synthesis and cellular location of the ten influenza polypeptides individually expressed by recombinant vaccinia viruses. Virology (1987) 3.53
Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. Proc Natl Acad Sci U S A (1996) 3.29
Cross-subtype protection in humans during sequential, overlapping, and/or concurrent epidemics caused by H3N2 and H1N1 influenza viruses. J Infect Dis (1985) 2.86
Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein. Vaccine (2005) 2.82
Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1. Clin Infect Dis (2011) 2.71
Primary influenza A virus infection induces cross-protective immunity against a lethal infection with a heterosubtypic virus strain in mice. Vaccine (2006) 2.59
Influenza vaccines for the future. N Engl J Med (2010) 2.54
Cross-recognition of avian H5N1 influenza virus by human cytotoxic T-lymphocyte populations directed to human influenza A virus. J Virol (2008) 2.24
Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb Mortal Wkly Rep (2011) 2.24
Vaccines for seasonal and pandemic influenza. J Infect Dis (2006) 2.14
A novel role for non-neutralizing antibodies against nucleoprotein in facilitating resistance to influenza virus. J Immunol (2008) 2.10
Analysis of the evolution and variation of the human influenza A virus nucleoprotein gene from 1933 to 1990. J Virol (1993) 2.01
Preparing for pandemic vaccination: an international policy agenda for vaccine development. J Public Health Policy (2005) 2.00
Cross-subtype immunity against avian influenza in persons recently vaccinated for influenza. Emerg Infect Dis (2008) 1.98
Protective CD4+ and CD8+ T cells against influenza virus induced by vaccination with nucleoprotein DNA. J Virol (1998) 1.82
Preliminary assessment of the efficacy of a T-cell-based influenza vaccine, MVA-NP+M1, in humans. Clin Infect Dis (2012) 1.82
Contributions of antinucleoprotein IgG to heterosubtypic immunity against influenza virus. J Immunol (2011) 1.74
The genesis of a pandemic influenza virus. Cell (2005) 1.73
Evolutionarily conserved protein sequences of influenza a viruses, avian and human, as vaccine targets. PLoS One (2007) 1.72
Purified influenza virus nucleoprotein protects mice from lethal infection. J Gen Virol (1987) 1.62
Making better influenza virus vaccines? Emerg Infect Dis (2006) 1.59
Cutting edge: rapid in vivo CTL activity by polyoma virus-specific effector and memory CD8+ T cells. J Immunol (2003) 1.55
Efficacious recombinant influenza vaccines produced by high yield bacterial expression: a solution to global pandemic and seasonal needs. PLoS One (2008) 1.44
Vaccination focusing immunity on conserved antigens protects mice and ferrets against virulent H1N1 and H5N1 influenza A viruses. Vaccine (2009) 1.42
The roles of influenza virus haemagglutinin and nucleoprotein in protection: analysis using vaccinia virus recombinants. Scand J Immunol (1987) 1.41
B cells promote resistance to heterosubtypic strains of influenza via multiple mechanisms. J Immunol (2008) 1.35
Regulation of antinucleoprotein IgG by systemic vaccination and its effect on influenza virus clearance. J Virol (2011) 1.35
Vaccine development strategies for improving immunization: the role of modern immunology. Nat Immunol (2004) 1.27
Partial protection against H5N1 influenza in mice with a single dose of a chimpanzee adenovirus vector expressing nucleoprotein. Vaccine (2007) 1.26
Vaxfectin-formulated influenza DNA vaccines encoding NP and M2 viral proteins protect mice against lethal viral challenge. Hum Vaccin (2007) 1.23
Comparison of vaccines for induction of heterosubtypic immunity to influenza A virus: cold-adapted vaccine versus DNA prime-adenovirus boost strategies. Vaccine (2008) 1.20
Intranasal immunization with synthetic recombinant vaccine containing multiple epitopes of influenza virus. Vaccine (2002) 1.19
Preparation, characterization, and immunogenicity in mice of a recombinant influenza H5 hemagglutinin vaccine against the avian H5N1 A/Vietnam/1203/2004 influenza virus. Vaccine (2009) 1.14
Immunization with influenza A NP-expressing vaccinia virus recombinant protects mice against experimental infection with human and avian influenza viruses. Arch Virol (2005) 1.11
Dose dependence of CTL precursor frequency induced by a DNA vaccine and correlation with protective immunity against influenza virus challenge. J Immunol (1999) 1.10
An influenza A/H1N1/2009 hemagglutinin vaccine produced in Escherichia coli. PLoS One (2010) 0.97
Candidate influenza vaccines based on recombinant modified vaccinia virus Ankara. Expert Rev Vaccines (2009) 0.96
Subtype cross-reactive, infection-enhancing antibody responses to influenza A viruses. J Virol (1994) 0.94
Protection against mouse and avian influenza A strains via vaccination with a combination of conserved proteins NP, M1 and NS1. Influenza Other Respir Viruses (2007) 0.93
Protection against multiple influenza A virus subtypes by intranasal administration of recombinant nucleoprotein. Arch Virol (2010) 0.92
A preliminary study on the immunogenicity in rabbits and in human volunteers of a recombinant vaccinia virus expressing Epstein-Barr virus membrane antigen. Chin Med Sci J (1991) 0.84
Heterosubtypic immunity to influenza mediated by liposome adjuvanted H5N1 recombinant protein vaccines. Vaccine (2010) 0.83
Mutant influenza A virus nucleoprotein is preferentially localized in the cytoplasm and its immunization in mice shows higher immunogenicity and cross-reactivity. Vaccine (2007) 0.83
Moving influenza vaccines forward. Expert Rev Vaccines (2009) 0.82
[Efficient soluble expression and purification of influenza A nucleoprotein in Escherichia coli]. Bing Du Xue Bao (2011) 0.77
International network of cancer genome projects. Nature (2010) 20.35
Sequencing of 50 human exomes reveals adaptation to high altitude. Science (2010) 11.27
Rapid "open-source" engineering of customized zinc-finger nucleases for highly efficient gene modification. Mol Cell (2008) 11.24
Resequencing of 200 human exomes identifies an excess of low-frequency non-synonymous coding variants. Nat Genet (2010) 5.44
Frequent mutations of genes encoding ubiquitin-mediated proteolysis pathway components in clear cell renal cell carcinoma. Nat Genet (2011) 3.66
Direct interaction between Nrf2 and p21(Cip1/WAF1) upregulates the Nrf2-mediated antioxidant response. Mol Cell (2009) 3.50
Using VAAST to identify an X-linked disorder resulting in lethality in male infants due to N-terminal acetyltransferase deficiency. Am J Hum Genet (2011) 3.43
Surgery with molecular fluorescence imaging using activatable cell-penetrating peptides decreases residual cancer and improves survival. Proc Natl Acad Sci U S A (2010) 3.41
Activatable cell penetrating peptides linked to nanoparticles as dual probes for in vivo fluorescence and MR imaging of proteases. Proc Natl Acad Sci U S A (2010) 3.03
A noncanonical mechanism of Nrf2 activation by autophagy deficiency: direct interaction between Keap1 and p62. Mol Cell Biol (2010) 2.93
Complete resequencing of 40 genomes reveals domestication events and genes in silkworm (Bombyx). Science (2009) 2.68
Integrated approach for the identification of human hepatocyte nuclear factor 4alpha target genes using protein binding microarrays. Hepatology (2010) 2.51
Efficient and robust feature extraction by maximum margin criterion. IEEE Trans Neural Netw (2006) 2.32
Roscovitine targets, protein kinases and pyridoxal kinase. J Biol Chem (2005) 2.31
Prevalence of the initiator over the TATA box in human and yeast genes and identification of DNA motifs enriched in human TATA-less core promoters. Gene (2006) 2.31
In vivo characterization of activatable cell penetrating peptides for targeting protease activity in cancer. Integr Biol (Camb) (2009) 2.30
Strong influence of human leukocyte antigen (HLA)-DP gene variants on development of persistent chronic hepatitis B virus carriers in the Han Chinese population. Hepatology (2011) 2.24
Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism. Proc Natl Acad Sci U S A (2011) 2.22
Comprehensive comparison of three commercial human whole-exome capture platforms. Genome Biol (2011) 2.15
MSOAR: a high-throughput ortholog assignment system based on genome rearrangement. J Comput Biol (2007) 2.14
The Mg-chelatase H subunit of Arabidopsis antagonizes a group of WRKY transcription repressors to relieve ABA-responsive genes of inhibition. Plant Cell (2010) 2.13
Genomic segmental polymorphisms in inbred mouse strains. Nat Genet (2004) 1.93
Estimation of allele frequency and association mapping using next-generation sequencing data. BMC Bioinformatics (2011) 1.93
Efficient inference of haplotypes from genotypes on a pedigree. J Bioinform Comput Biol (2003) 1.89
Association between variants of PRDM1 and NDP52 and Crohn's disease, based on exome sequencing and functional studies. Gastroenterology (2013) 1.83
Understanding high grade glioma: molecular mechanism, therapy and comprehensive management. Cancer Lett (2013) 1.82
Computing the minimum recombinant haplotype configuration from incomplete genotype data on a pedigree by integer linear programming. J Comput Biol (2005) 1.78
Systemic in vivo distribution of activatable cell penetrating peptides is superior to that of cell penetrating peptides. Integr Biol (Camb) (2009) 1.78
Enhancement of hepatitis B virus replication by its X protein in transgenic mice. J Virol (2002) 1.78
IsoLasso: a LASSO regression approach to RNA-Seq based transcriptome assembly. J Comput Biol (2011) 1.76
MiR-221 and miR-222 target PUMA to induce cell survival in glioblastoma. Mol Cancer (2010) 1.74
Inference of isoforms from short sequence reads. J Comput Biol (2011) 1.72
Regulation of hair follicle development by the TNF signal ectodysplasin and its receptor Edar. Development (2002) 1.70
Regulation of renal lipid metabolism, lipid accumulation, and glomerulosclerosis in FVBdb/db mice with type 2 diabetes. Diabetes (2005) 1.70
Molecular classification of gliomas based on whole genome gene expression: a systematic report of 225 samples from the Chinese Glioma Cooperative Group. Neuro Oncol (2012) 1.66
Assignment of orthologous genes via genome rearrangement. IEEE/ACM Trans Comput Biol Bioinform (2006) 1.66
Laboratory diagnosis of four recent sporadic cases of community-acquired SARS, Guangdong Province, China. Emerg Infect Dis (2004) 1.65
A small-molecule inducer of the antioxidant response element. Chem Biol (2010) 1.65
ChemmineR: a compound mining framework for R. Bioinformatics (2008) 1.64
Regulation of renal fatty acid and cholesterol metabolism, inflammation, and fibrosis in Akita and OVE26 mice with type 1 diabetes. Diabetes (2006) 1.64
Crosstalk between Aurora-A and p53: frequent deletion or downregulation of Aurora-A in tumors from p53 null mice. Cancer Cell (2007) 1.59
Natural selection affects multiple aspects of genetic variation at putatively neutral sites across the human genome. PLoS Genet (2011) 1.54
The Wilms tumor gene, Wt1, is critical for mouse spermatogenesis via regulation of sertoli cell polarity and is associated with non-obstructive azoospermia in humans. PLoS Genet (2013) 1.52
Exome sequencing and unrelated findings in the context of complex disease research: ethical and clinical implications. Discov Med (2011) 1.52
Circulating microRNAs in cancer: origin, function and application. J Exp Clin Cancer Res (2012) 1.50
Real-time in vivo molecular detection of primary tumors and metastases with ratiometric activatable cell-penetrating peptides. Cancer Res (2012) 1.50
Identifying transcription factor binding sites through Markov chain optimization. Bioinformatics (2002) 1.50
High-responsivity graphene/InAs nanowire heterojunction near-infrared photodetectors with distinct photocurrent on/off ratios. Small (2014) 1.49
HOTAIR, a cell cycle-associated long noncoding RNA and a strong predictor of survival, is preferentially expressed in classical and mesenchymal glioma. Neuro Oncol (2013) 1.47
Experimental verification of reversed Cherenkov radiation in left-handed metamaterial. Phys Rev Lett (2009) 1.47
Protective effect of nicotine on lipopolysaccharide-induced acute lung injury in mice. Respiration (2010) 1.46
The magnesium-chelatase H subunit binds abscisic acid and functions in abscisic acid signaling: new evidence in Arabidopsis. Plant Physiol (2009) 1.44
Analysis of bacterial community composition by oligonucleotide fingerprinting of rRNA genes. Appl Environ Microbiol (2002) 1.41
The development of 7E chromosome-specific molecular markers for Thinopyrum elongatum based on SLAF-seq technology. PLoS One (2013) 1.40
A maximum common substructure-based algorithm for searching and predicting drug-like compounds. Bioinformatics (2008) 1.38
A broadly flavivirus cross-neutralizing monoclonal antibody that recognizes a novel epitope within the fusion loop of E protein. PLoS One (2011) 1.36
The chemokine CXCL12 and its receptor CXCR4 promote glioma stem cell-mediated VEGF production and tumour angiogenesis via PI3K/AKT signalling. J Pathol (2011) 1.36
Expression of hypoxia-inducible factor-1 alpha and associated proteins in pancreatic ductal adenocarcinoma and their impact on prognosis. Int J Oncol (2007) 1.35
Transcriptome assembly and isoform expression level estimation from biased RNA-Seq reads. Bioinformatics (2012) 1.34
Whole-genome microRNA expression profiling identifies a 5-microRNA signature as a prognostic biomarker in Chinese patients with primary glioblastoma multiforme. Cancer (2012) 1.33
Uncover disease genes by maximizing information flow in the phenome-interactome network. Bioinformatics (2011) 1.32
Etiology and clinical characterization of respiratory virus infections in adult patients attending an emergency department in Beijing. PLoS One (2012) 1.31
MicroRNA roles in beta-catenin pathway. Mol Cancer (2010) 1.30
Learning curve of transumbilical single incision laparoscopic cholecystectomy (SILS): a preliminary study of 80 selected patients with benign gallbladder diseases. World J Surg (2011) 1.30
Crystal structure of the carnitine transporter and insights into the antiport mechanism. Nat Struct Mol Biol (2010) 1.30
miR-181d: a predictive glioblastoma biomarker that downregulates MGMT expression. Neuro Oncol (2012) 1.29
Diabetic nephropathy is accelerated by farnesoid X receptor deficiency and inhibited by farnesoid X receptor activation in a type 1 diabetes model. Diabetes (2010) 1.29
OligoSpawn: a software tool for the design of overgo probes from large unigene datasets. BMC Bioinformatics (2006) 1.28
Haplotype-based linkage disequilibrium mapping via direct data mining. Bioinformatics (2005) 1.28
MiR-181d acts as a tumor suppressor in glioma by targeting K-ras and Bcl-2. J Cancer Res Clin Oncol (2011) 1.27
Correlation of IDH1 mutation with clinicopathologic factors and prognosis in primary glioblastoma: a report of 118 patients from China. PLoS One (2012) 1.27
Structure of the fusion core and inhibition of fusion by a heptad repeat peptide derived from the S protein of Middle East respiratory syndrome coronavirus. J Virol (2013) 1.26
Short-term and medium-term clinical outcomes of laparoscopic-assisted and open surgery for colorectal cancer: a single center retrospective case-control study. BMC Gastroenterol (2011) 1.25
Induction of angiogenesis in tissue-engineered scaffolds designed for bone repair: a combined gene therapy-cell transplantation approach. Proc Natl Acad Sci U S A (2008) 1.25
IL28B genetic variation is associated with spontaneous clearance of hepatitis C virus, treatment response, serum IL-28B levels in Chinese population. PLoS One (2012) 1.25
VHL regulates the effects of miR-23b on glioma survival and invasion via suppression of HIF-1α/VEGF and β-catenin/Tcf-4 signaling. Neuro Oncol (2012) 1.24
Extensive X-linked adaptive evolution in central chimpanzees. Proc Natl Acad Sci U S A (2012) 1.23
The structural and accessory proteins M, ORF 4a, ORF 4b, and ORF 5 of Middle East respiratory syndrome coronavirus (MERS-CoV) are potent interferon antagonists. Protein Cell (2013) 1.23
Confirmation by exome sequencing of the pathogenic role of NCSTN mutations in acne inversa (hidradenitis suppurativa). J Invest Dermatol (2011) 1.23
Manipulating electromagnetic wave polarizations by anisotropic metamaterials. Phys Rev Lett (2007) 1.22
Computational prediction of operons in Synechococcus sp. WH8102. Genome Inform (2004) 1.22
MiR-410 regulates MET to influence the proliferation and invasion of glioma. Int J Biochem Cell Biol (2012) 1.22
Nrf2 promotes neuronal cell differentiation. Free Radic Biol Med (2009) 1.22
Plasma IGFBP-2 levels predict clinical outcomes of patients with high-grade gliomas. Neuro Oncol (2009) 1.20
Computational prediction of type III secreted proteins from gram-negative bacteria. BMC Bioinformatics (2010) 1.19
High-performance affinity monolith chromatography: development and evaluation of human serum albumin columns. Anal Chem (2004) 1.18
Inhibition of STAT3 activity with AG490 decreases the invasion of human pancreatic cancer cells in vitro. Cancer Sci (2006) 1.18
Antitumor activity of chloroform fraction of Scutellaria barbata and its active constituents. Phytother Res (2007) 1.18
Crystal structure of the neurotrophin-3 and p75NTR symmetrical complex. Nature (2008) 1.18
Early second-trimester serum miRNA profiling predicts gestational diabetes mellitus. PLoS One (2011) 1.18
Identification of MMP-9 specific microRNA expression profile as potential targets of anti-invasion therapy in glioblastoma multiforme. Brain Res (2011) 1.17
Profiling the DNA-binding specificities of engineered Cys2His2 zinc finger domains using a rapid cell-based method. Nucleic Acids Res (2007) 1.17
The farnesoid X receptor modulates renal lipid metabolism and diet-induced renal inflammation, fibrosis, and proteinuria. Am J Physiol Renal Physiol (2009) 1.16
Modulation of carbohydrate response element-binding protein gene expression in 3T3-L1 adipocytes and rat adipose tissue. Am J Physiol Endocrinol Metab (2004) 1.16
Adenanthin targets peroxiredoxin I and II to induce differentiation of leukemic cells. Nat Chem Biol (2012) 1.15
Primate-specific miR-663 functions as a tumor suppressor by targeting PIK3CD and predicts the prognosis of human glioblastoma. Clin Cancer Res (2014) 1.15
Structure and functional implications of the human rad9-hus1-rad1 cell cycle checkpoint complex. J Biol Chem (2009) 1.14
SEED: efficient clustering of next-generation sequences. Bioinformatics (2011) 1.14